Opendata, web and dolomites

PICARD SIGNED

DISRUPTIVE GPCR LEAD DISCOVERY PLATFORM DELIVERING NEW AND SAFER THERAPEUTICS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PICARD project word cloud

Explore the words cloud of the PICARD project. It provides you a very rough idea of what is the project "PICARD" about.

gt    drugs    exploited    markets    15    commercialization    platform    remarkably    time    12    longer    scherrer    acquire    untapped    rate    protein    entry    risks    eth    vivo    940    start    technologies    extremely    intelligence    pilot    artificial    animal    150    dramatically    produces    discovery    customers    predictability    provides    gpcrs    model    desired    picard    market    pharmaceutical    71       interax    stages    sizeable    designed    combines    clinical    experimental    global    reducing    economic    barriers    right    million    off    companies    biotech    lower    investment    levels    company    creates    billion    strategy    industry    opportunity    seven    moment    services    business    least    40    biology    paul    trials    innovative    intend    coupled    holistic    80    70    savings    custom    zero    receptors    compounds    efficiency    pharmacologically    candidates    drug    spin    uses    uuml    probability    differentiates    devised    outsourcing    swiss    service    data      

Project "PICARD" data sheet

The following table provides information about the project.

Coordinator
INTERAX BIOTECH AG 

Organization address
address: PARK INNOVAARE
city: VILLINGEN
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 2˙493˙167 €
 EC max contribution 1˙745˙217 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INTERAX BIOTECH AG CH (VILLINGEN) coordinator 1˙745˙217.00

Map

 Project objective

InterAx Biotech, a Swiss company and spin-off from the ETH Zürich and the Paul Scherrer Institute, has built PICARD, an innovative and unique lead discovery platform for the design and selection of better drug candidates. PICARD combines a systems biology approach with experimental data and uses artificial intelligence methods to design novel compounds with the desired properties. This holistic approach differentiates PICARD from technologies now used in the pharmaceutical industry. Our systems biology approach provides PICARD with in vivo predictability, dramatically reducing the need for animal testing (60-80%) and increasing the probability of success of drug candidates in clinical trials. At the moment, the success rate in clinical trials is lower than 12%. This produces sizeable costs (€2.3 billion) and extremely long time to market (15 years or longer) in drug development. We offer custom-designed PICARD services to pharmaceutical and biotech companies that are outsourcing key stages of their drug discovery process. PICARD remarkably increases the efficiency of the drug discovery process, offering our customers economic savings of at least €150.7 million per developed drug and a reduction of time to market to 10 years. PICARD focuses on G-Protein Coupled Receptors (GPCRs), which are the target of 40% of the developed drugs. However, >70% of the pharmacologically relevant GPCRs are yet to be exploited, which creates an untapped global market opportunity of €71.2 billion. We intend to acquire, in seven years, 1-2% of the European and US available markets (€940 million). To achieve this goal, we have designed a business model in which PICARD is offered at increasing levels of support, investment and risks for our customers: service projects, pilot projects and long term partnerships. This strategy is devised to lower market entry barriers, allowing us to start commercialization right after Phase 2 execution, with a zero time to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More